Condition
Protein-Losing Enteropathies
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03322345Terminated
Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy
NCT02315898Phase 2Completed
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
NCT04163653Completed
Lymphatic Morphology of Fontan Patients
NCT03950804Unknown
Transcriptome and Metabolic Analyses of CHAPLE Disease
Showing all 4 trials